Gyre Therapeutics, Inc.
NASDAQ:GYRE · NASDAQ Capital Market
+$0.00 today
Vol 0.06M · Avg 0.09M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $9.9M -44.8% | $17.9M +120.9% | -$85.5M -2081.5% | $4.3M +104.9% | -$87.9M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $2.5M +56.2% | $1.6M +42.5% | $1.1M -1.3% | $1.1M +289.3% | $290.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$1.1M -10.7% | -$1.0M +13.6% | -$1.2M -38.4% | -$838.0K +78.4% | -$3.9M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $7.2M +761.3% | $831.0K -88.6% | $7.3M -45.5% | $13.4M +292.5% | $3.4M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$15.6M +0.9% | -$15.7M -310.4% | $7.5M +195.7% | -$7.8M -1714.3% | $483.0K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$12.0M -28.7% | -$9.3M -813.1% | $1.3M +116.4% | -$7.9M -629.8% | $1.5M | $592.6M | $1.3B | $626.2M |
| Inventory | -$3.6M -69.8% | -$2.1M -222.4% | $1.7M +298.7% | -$879.0K -122.7% | $3.9M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $13.0K +105.3% | -$245.0K -227.6% | $192.0K +271.4% | -$112.0K -122.4% | $500.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $17.0K +100.4% | -$4.0M -195.3% | $4.2M +278.5% | $1.1M +120.7% | -$5.4M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$1.8M +74.6% | -$7.3M -107.5% | $96.7M +19120.5% | $503.0K -87.1% | $3.9M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $1.0M +127.7% | -$3.6M -114.1% | $25.9M +142.5% | $10.7M +112.7% | -$83.8M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$1.2M +62.0% | -$3.1M +63.6% | -$8.6M -71.8% | -$5.0M -495.7% | -$839.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $30.0K +101.8% | -$1.7M -141.9% | $4.0M +401.9% | -$1.3M | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 +100.0% | -$15.5M +1.7% | -$15.7M -110.2% | -$7.5M | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 -100.0% | $49.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $686.0K +266.5% | -$412.0K -187.5% | $471.0K +3723.1% | -$13.0K | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$474.0K +97.6% | -$19.9M -0.6% | -$19.8M -43.0% | -$13.8M -128.7% | $48.2M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 +100.0% | -$6.7M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $25.9M +3246.1% | $773.0K | $0 | $0 -100.0% | $49.6M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$1.5M -211.9% | $1.3M | $0 | $0 -100.0% | $6.7M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $24.4M +1059.8% | $2.1M -15.9% | $2.5M | $0 -100.0% | $49.6M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $343.0K +225.6% | -$273.0K +8.4% | -$298.0K +84.2% | -$1.9M | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $25.3M +216.4% | -$21.7M -360.3% | $8.3M +265.8% | -$5.0M -135.9% | $14.0M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$180.0K +97.3% | -$6.8M -139.1% | $17.3M +204.7% | $5.7M +106.7% | -$84.6M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.28B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.48B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.42B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.40B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.37B
MeiraGTx Holdings plc
NASDAQ:MGTX
$1.03B
Astria Therapeutics, Inc.
ATXS
$718.13M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$471.21M
Keros Therapeutics, Inc.
NASDAQ:KROS
$336.46M
Anavex Life Sciences Corp.
NASDAQ:AVXL
$244.19M
SEC Filings
Recent regulatory filings
No filings found.
Does GYRE generate free cash flow?
Gyre Therapeutics, Inc. (GYRE) generated -$180,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does GYRE produce?
Operating cash flow was $1.01M, before capital expenditures of $1.19M.
Explore More
Continue the stock analysis
Jump to another research area for this company.